Applied Biosystems
This article was originally published in The Gray Sheet
Executive Summary
Applera Corp. unit submits 510(k) for ViroSeq HIV-1 genotyping system under FDA accelerated de novo review process, firm announces July 31. The system is designed to detect spontaneously-developed drug resistance in the HIV-1 virus genome by targeting protease and reverse transcriptase genes
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.